いろいろ aasld hepatitis b 326626-Aasld hepatitis b guidelines 2019
AASLD designates this live activity for a maximum of 700 AMA PRA Category 1 Credits Dr Brown has served in advisory roles for the Hepatitis B Foundation (Board of Directors), the NIH Div of Extramural Grants, FDA's Div of Antiviral Products (Aug 02 HBV advisory meeting), and various pharma/biotech companies In a study presented during AASLD 08, 2 cirrhotic patients with chronic hepatitis B were treated with either lamivudine, adefovir, or adefovir in denovo combination with lamivudine* for up to 48 months The study authors found a significant difference in the rate of drug resistance, with only 6% of the combination arm developing mutationsMission To promote national and international collaboration to promote clinical care and research in the field of the hepatitis B virus (HBV) To improve awareness among health care professionals and the public regarding the prevention of HBV, screening high risk populations for HBV and management of chronic HBV based on AASLD Guidelines Hepatit...
